Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,743,000 | 2,177,000 | 1,827,000 | 2,402,000 | 1,804,000 |
| Receivables | 4,572,000 | 4,581,000 | 4,385,000 | 4,545,000 | 5,189,000 |
| Inventories | 4,406,000 | 4,403,000 | 4,516,000 | 4,361,000 | 4,290,000 |
| Other current assets | 738,000 | 899,000 | 537,000 | 517,000 | 624,000 |
| TOTAL | $12,401,000 | $13,005,000 | $12,160,000 | $12,781,000 | $12,884,000 |
| Non-Current Assets | |||||
| PPE Net | 6,112,000 | 6,296,000 | 6,152,000 | 6,122,000 | 6,221,000 |
| Intangibles | 28,747,000 | 29,547,000 | 29,536,000 | 34,556,000 | 34,746,000 |
| Other Non-Current Assets | 1,744,000 | 1,792,000 | 1,888,000 | 1,532,000 | 1,479,000 |
| TOTAL | $36,603,000 | $37,635,000 | $37,576,000 | $42,210,000 | $42,446,000 |
| Total Assets | $49,004,000 | $50,640,000 | $49,737,000 | $54,991,000 | $55,330,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 2,697,000 | 3,188,000 | 2,106,000 | 1,649,000 | 1,630,000 |
| Accounts payable and accrued liabilities | 1,692,000 | 1,756,000 | 1,716,000 | 1,606,000 | 1,710,000 |
| Accrued Expenses | 2,377,000 | 2,465,000 | 2,336,000 | 2,299,000 | 2,258,000 |
| Other current liabilities | 5,323,000 | 5,757,000 | 5,944,000 | 6,196,000 | 6,723,000 |
| TOTAL | $12,089,000 | $13,164,000 | $12,103,000 | $11,751,000 | $12,322,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 22,288,000 | 22,731,000 | 23,515,000 | 24,616,000 | 24,473,000 |
| Other Non-Current Liabilities | 2,654,000 | 2,707,000 | 2,643,000 | 2,912,000 | 3,079,000 |
| TOTAL | $25,940,000 | $26,414,000 | $27,042,000 | $28,416,000 | $28,420,000 |
| Total Liabilities | $38,029,000 | $39,579,000 | $39,145,000 | $40,167,000 | $40,742,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,102,349 | 1,096,512 | 1,095,972 | 1,095,777 | 1,095,525 |
| Common Shares | 57,000 | 57,000 | 57,000 | 57,000 | 56,000 |
| Retained earnings | -10,869,000 | -10,946,000 | -11,096,000 | -6,747,000 | -6,887,000 |
| Other shareholders' equity | -1,559,000 | -1,365,000 | -1,644,000 | -1,732,000 | -1,795,000 |
| TOTAL | $10,975,000 | $11,061,000 | $10,592,000 | $14,824,000 | $14,588,000 |
| Total Liabilities And Equity | $49,004,000 | $50,640,000 | $49,737,000 | $54,991,000 | $55,330,000 |